CRISPRMED25 Speakers (early confirmation)

Scientific Conference (virtual, April 7, 2025 | in-person, April 8-11, 2025)

Keynote Speaker: Virginijus Šikšnys, Prof., Ph.D., Head of Department, Vilnius University, Lithuania

Patient Advocate: Jimi Olaghere is a CASGEVY recipient who has developed a keen interest in the advancements of cell and gene therapies, since his transformative participation in the groundbreaking clinical trial. Jimi is passionate about the positive impact that these therapies can have on patients in need and has become a staunch advocate for increased accessibility of gene therapies for sickle cell disease patients worldwide. At CRISPRMED25, Jimi will share his story about living with sickle cell disease, before and after treatment with the recently approved CRISPR therapy CASGEVY.

• Dolça Rogers, Ph.D., ATMP topic lead, Pharmaceutical Quality Office, European Medicines Agency (EMA), Netherlands
• Emma Wang, Ph.D., CTO, YolTech Therapeutics, China
• Alvin Luk, Co-Founder, CEO, and Head of Medical at HuidaGene Therapeutics, Inc., US
• Jakob Giehm Mikkelsen, Prof., Ph.D., Aarhus University, Denmark
• Annarita Miccio, Group Leader, Ph.D., Imagine Institute of Genetic Diseases, France
• Blair Madison, Ph.D., Chief Scientific Officer, Gene Therapy at Poseida Therapeutics, US
• Matthew Porteus, Prof., MD, Ph.D., Stanford Medicine, US
• Raffaella Di Micco, Group Leader, Ph.D., SR-TIGET, Italy
• Jacob Corn, Prof., Ph.D., ETH Zürich, Switzerland
• Gerald Schwank, Prof., Ph.D., University of Zürich, Switzerland
• Julian Grünewald, Ass. Prof., MD, Ph.D., Technical University of Munich, Germany
• William H. Peranteau, MD, Surgeon and Professor, University of Pennsylvania/Children’s Hospital of Philadelphia, US
• Guillermo Montoya, Prof., Research Director and Group Leader at the Protein Structure and Function program at CPR, University of Copenhagen, Denmark
• Kiana Aran, Associate Professor of Bioengineering and Medicine, University of California San Diego, US
• Suk See De Ravin, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), US
• Rasmus O. Bak, Ass. Prof. and Group Leader, Aarhus University, Denmark
• Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
• Ayal Hendel, Principal Investigator and Group Leader, Bar-Ilan University, Israel
• Alessia Cavazza, Ass. Prof., Group Leader, Infection, Immunity & Inflammation Department at University College London's Great Ormond Street Institute of Child Health, England
• Anna Cereseto, Prof., Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy
• Xavier Duportet, Ph.D., CEO and Co-founder, Eligo Biosciences
• TBD, Life Edit Therapeutics, US
• TBD, ReCode Therapeutics, US

Startup-Investor Event "Invest in Future CRISPR Medicine | Develop Future Medicine" (in-person, April 8, 2025)

• Michael Krohn, Co-CEO, Akribion Genomics, Germany
• Jiawei Lee, Co-founder and Chief Business Officer, QUiCKR Bio, US
• Jan Nelis, Project Lead and Co-Founder, Ariya Bio, Switzerland
• Michael Jackson, Venture Capitalist
• ...